Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.62 |
| ▸ | CA2 | P00918 | 8/20 | 0.62 |
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16383779 | 0.93 | CA1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL16344311 | 0.93 | CA1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL2328368 | 0.90 | CA1 (0.61) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL5015557 | 0.88 | CA1 (0.59) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL15032923 | 0.88 | CA1 (0.59) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17809681 | 0.86 | CA1 (0.53) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17809675 | 0.86 | CA1 (0.53) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL30521147 | 0.86 | CA1 (0.60) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL16383769 | 0.86 | CA1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL16627553 | 0.86 | CA1 (0.53) | CA1CA2CA12CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10167266-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-1922073-B1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1922073-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070265280-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007018640-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1485360-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | CYFI, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1485360-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-10167266-B2 | Sodium channel blockers | SCNN1B, SCNN1A, SCNN1G | CA1 656/4885CA2 203/4885CA12 610/4885 |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-20070265280-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | CA1 589/4885CA2 176/4885CA12 1314/4885 |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | ADRB2, ADRB3, ADRA1D | CA1 3670/4885CA2 138/4885CA12 1619/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | CA1 1345/4885CA2 165/4885CA12 1452/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | CA1 589/4885CA2 176/4885CA12 1314/4885 |
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.